In its Q322 report, Mendus highlighted key developments in the period, and some significant post-per...
Gross margin up 5.2pp, mostly on Russia sales mix We increase adj.
Företagsparken grows despite macro headwinds Q3 NAV decline largely explains estimate cuts Share tra...
Reversals and deferred tax behind net profit beat… …while the full effect of rate hikes awaits 2024e...
Med Q3-rapporten presenterad står det klart att Koncernen överträffade vårt försäljningsestimat, var...
Redeye embraces another quarter of continuous sales growth and key activities in its clinical trial ...
Redeye is sad to hear that CEO Anders Kottenauer is leaving the company.
Redeye states the Q3 report was strong across the board.
We expect a decent Q3 report on 18 November. We forecast group sales will grow 28% (2 pp organic), u...
Ferronordic's Q3 report was better than we expected, driven by good sales mix in Russia/CIS.
Redeye retains its positive view of CombinedX following a soft Q3 report, hurt by high employee turn...
Redeye endorses today’s news from Heliospectra, an order of USD780,000 from an American AgTech compa...
Learning to Sleep publicerade den 11 november 2022 bolagets delårsrapport för det tredje kvartalet 2...
Supply chain issues and shortages continue to hit Boule Missed sales by 13% and EBIT by 80% vs.
Redeye comments on Mendus’ Q3 2022 report, as the company is approaching a crucial survival readout ...
Prostatype are making good European launch progress with clinical evaluations, ongoing evaluations a...
Redeye comments on Isofol’s Q3 2022 report, and we expect the company to communicate a clearer path ...
Ett svagt kvartal Bolagets nettoomsättning uppgick till 1,0 mkr (3,6 mkr) och rörelseresultatet blev...
Försäljningen i gång på de viktigaste europeiska marknaderna Allt fokus är på lanseringen av hästvac...
Omsättning något över våra estimat Omsättningen uppgick till EUR 12,9m vs våra estimat om EUR 12,3, ...
